Saunders Family Professor of Neurology, and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai
Future of Relapsing MS Management
Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.
Biomarkers for Monitoring Treatment Response in Relapsing MS
Expert neurologists discuss current and future biomarkers relevant to relapsing multiple sclerosis including cerebrospinal fluid neurofilament.
Exciting Multiple Sclerosis Debates at IFN 2021: Fred Lublin, MD
The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.
Shared Decision Making and Lifestyle Issues in Relapsing MS
A panel of experts emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.
Sequencing Therapies in Relapsing MS
Experts in multiple sclerosis (MS) discuss key factors involved in the sequencing of therapies for relapsing MS.
Monitoring Outcomes in Relapsing MS
Lauren Gluck, MD discusses considerations for monitoring response to treatment in relapsing multiple sclerosis.
Overview of Teriflunomide for Relapsing MS
Lauren Gluck, MD, and Ravi Dukkipati, MD, provide an overview of teriflunomide for relapsing multiple sclerosis including its safety and tolerability profile.
Considerations for the Use of Fumarates in Relapsing MS
Experts in the field of multiple sclerosis provide insight into the fumarates as a viable oral option for relapsing MS.
Anti-CD20 Agents for Relapsing MS
A panel of experts discuss the use of anti-CD20 monoclonal antibodies in relapsing multiple sclerosis including summaries of the phase III ORATORIO and ASCLEPIOS trials, for ocrelizumab and ofatumumab, respectively.
Role of S1P Receptor Modulators in Relapsing MS
Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.
Cladribine in Relapsing MS
Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.
Cladribine: History and Mechanism of Action in MS
Gavin Giovannoni, MD provides an overview of the development and pharmacodynamics of cladribine in multiple sclerosis.
Platform Agents for MS: Interferons and Glatiramer
Fred D. Lublin, MD, Ravi Dukkipati, MD, and Lauren Gluck, MD, discuss interferons and glatiramer as platform therapies in multiple sclerosis.
Treatment Strategy for Relapsing MS
Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.
The Diagnosis of Multiple Sclerosis
Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.
Advice for Managing MS
Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.
Future of MS Management
Kristen Krysko, MD, and Robert Fox, MD, look to the future of multiple sclerosis management.
Exercise and MS Fatigue
Considerations regarding the role of exercise and combatting fatigue when treating patients with multiple sclerosis.
MS: Nutrition and Managing Cognitive Impairment
The importance of proper nutrition as a therapy for symptom control in multiple sclerosis and some strategies to manage cognitive impairment.
Shared Decision-Making and Complementary Therapies in Progressive MS
Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.
Age Considerations: Patients With Nonactive MS Progression
Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.
Monitoring Response in Progressive MS
Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.
Ibudilast for Progressive Treatment
Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.
Nonactive MS: Treatment Therapies
A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.
Patient Selection in MS Treatment
Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.
Progressive MS Treatment: Ocrelizumab
Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.
MS Treatment: EXPAND Study Versus ASCEND Study
Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.
Siponimod for SPMS Treatment
Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.
Treating PPMS Versus SPMS
A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.
Classification and Diagnosis of SPMS
Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.
2 Clarke Drive Cranbury, NJ 08512